Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

September 8, 2025

Primary Completion Date

July 30, 2027

Study Completion Date

July 30, 2027

Conditions
STOMACH NEOPLASMGastric CancerGastric Cancer Adenocarcinoma Metastatic
Interventions
DRUG

Lenvatinib

"Description: Lenvatinib: 12 mg (for body weight ≥ 60 kg) or 8 mg (for body weight \< 60 kg) per oral once daily~* Dose level 1: 8mg per oral once daily (for \<60kg) 12mg per oral once daily (for ≥ 60kg)~* Dose level 2: 4mg per oral once daily (for \<60kg) 8mg per oral once daily (for ≥ 60kg) Nivolumab: 360 mg administered intravenously every 3 weeks Chemotherapy(Oxaliplatin+Capecitabine) every 3 weeks~* Capecitabine 1000 mg/m² per oral twice daily on Days 1-14~* Oxaliplatin 130 mg/m² administered intravenously on Day 1"

Trial Locations (1)

05505

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER

NCT07149090 - Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites | Biotech Hunter | Biotech Hunter